公开(公告)号：US20130143237A1

公开(公告)日：2013-06-06

申请号：US13689407

申请日：2012-11-29

Applicant: Genentech, Inc.

Inventor： Siminder Atwal ,  Jo-Anne Hongo ,  Mark Lackner ,  Elizabeth Punnoose ,  Bonnee Rubinfeld ,  Rajesh Vij

IPC: G01N33/68 ,  C07K16/30

CPC classification number: G01N33/57434 ,  C07K16/3069 ,  C12N5/0693 ,  C12Y116/01 ,  C12Y301/03048 ,  G01N33/57492 ,  G01N2333/4742 ,  G01N2333/70596 ,  G01N2333/90287 ,  G01N2333/916 ,  G01N2800/52

Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.

Abstract translation: 本发明提供诊断前列腺癌的方法。 本发明还提供新的抗STEAP-1抗体及其用途。

公开(公告)号：US09632091B2

公开(公告)日：2017-04-25

申请号：US14919388

申请日：2015-10-21

Applicant: Genentech, Inc.

Inventor： Siminder Atwal ,  Jo-Anne Hongo ,  Mark Lackner ,  Elizabeth Punnoose ,  Bonnee Rubinfeld ,  Rajesh Vij

IPC: G01N33/53 ,  G01N33/574 ,  C07K16/30 ,  C12N5/09

CPC classification number: G01N33/57434 ,  C07K16/3069 ,  C12N5/0693 ,  C12Y116/01 ,  C12Y301/03048 ,  G01N33/57492 ,  G01N2333/4742 ,  G01N2333/70596 ,  G01N2333/90287 ,  G01N2333/916 ,  G01N2800/52

Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.

公开(公告)号：US11440969B2

公开(公告)日：2022-09-13

申请号：US16239663

申请日：2019-01-04

Applicant: Genentech, Inc.

Inventor： Mark Lackner ,  Daniel Maslyar ,  Yulei Wang ,  Walter Darbonne ,  Eric Humke

IPC: C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61K47/65 ,  A61P35/00 ,  A61K31/22 ,  A61K31/7048 ,  C07K16/28 ,  A61K39/00

Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.

公开(公告)号：US11021711B2

公开(公告)日：2021-06-01

申请号：US15838042

申请日：2017-12-11

Applicant: GENENTECH, Inc.

Inventor： Mark Lackner ,  Lukas C. Amler ,  Guy Cavet ,  Carol O'Brien ,  Ajay Pandita

IPC: C12Q1/6886 ,  C12N15/113 ,  A61K47/68

Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

公开(公告)号：US20180298387A1

公开(公告)日：2018-10-18

申请号：US15838042

申请日：2017-12-11

Applicant: GENENTECH, Inc.

Inventor： Mark Lackner ,  Lukas C. Amler ,  Guy Cavet ,  Carol O'Brien ,  Ajay Pandita

IPC: C12N15/113 ,  C12Q1/6886 ,  A61K47/68

Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.